Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Immunohistochemistry Stories

2012-05-31 02:25:17

TUCSON, Ariz., May 31, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein. This...

2012-05-21 10:24:08

BRANFORD, Conn., May 21, 2012 /PRNewswire/ -- HistoRx, the leader in quantitative immunohistochemistry, announces the application of their proprietary AQUA technology to assessment of messenger RNA in tissue. AQUA technology enables robust quantification and standardization of protein in tissue specimens; this new work extends the platform's capabilities beyond protein expression analysis to quantification of nucleic acids. AQUA technology was invented to address the challenges of...

2012-05-21 02:24:50

TUCSON, Ariz., May 21, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today that it has co-exclusively sub-licensed certain patents and patent applications from Gen-Probe Incorporated (GPRO) for the worldwide in vitro diagnostic (IVD) rights for measuring ERG protein expression through immunohistochemistry (IHC) in prostate tissue. The license complements the existing Ventana worldwide co-exclusive sublicense under certain patents and...

2012-05-16 14:22:12

GRAND RAPIDS, Mich. and GLOSTRUP, Denmark, May 16, 2012 /PRNewswire/ -- Van Andel Research Institute (VARI) and Dako, the Danish-based, worldwide supplier of cancer diagnostic tools today announce an agreement to license, manufacture and distribute cancer diagnostics utilizing the MET4 Antibody. The MET4 Antibody, developed by George F. Vande Woude, Ph.D. and Brian Cao, M.D. of VARI and Beatrice Knudsen, M.D., Ph.D., formerly of the Fred Hutchinson Cancer Research Center, has...

2012-04-22 23:00:53

The patented technology, now protected in both Europe and in the United States, enables perfect alignment of whole slide images at any magnification, independently of tissue type and staining. This is a central capability for the next generation of quantitative bio-marker analysis, and for time- and cost efficient whole slide stereology. Hoersholm, Denmark (PRWEB) April 23, 2012 Visiopharm A/S, a global leader in Quantitative Digital Pathology, announced today that the United States patent...

2012-04-16 02:28:25

IRVINE, Calif., April 16, 2012 /PRNewswire/ -- GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new monoclonal antibody against stage-specific embryonic antigen 5 (SSEA-5), a marker for human pluripotent stem cells (hPSCs) that may also improve the safety of stem cell-based treatments. (Photo: http://photos.prnewswire.com/prnh/20120416/LA87543) (Logo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b) The therapeutic potential of hPSCs...

2012-04-03 09:06:45

SU2C-funded study is the first to evaluate treatment based on molecular profiling of advanced pancreatic cancer The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare. The findings were announced during the American Association for Cancer Research...

2012-03-21 10:25:19

VANCOUVER, Canada, March 21, 2012 - bioTheranostics, Inc. announced today findings from three key studies. Results, presented at the United States and Canadian Academy of Pathology (USCAP) annual meeting, showed that CancerTYPE ID®( )had strong clinical utility and demonstrated a high level of accuracy for tumor classification and sub-classification. Tumor classification and sub-classification are important criteria in treatment selection with the advent of site- and subtype-specific...

2012-03-18 23:00:30

AMIRSYS, INC. announced today the update of its PathIQ ImmunoQuery product for pathologists. Salt Lake City, UT (PRWEB) March 18, 2012 AMIRSYS, INC. announced today the update of its PathIQ ImmunoQuery product for pathologists. This update adds the latest and most important references to the expert and evidence-based decision support system for immunohistochemistry representing over 24,500 cases. Carefully selected by Dr. Dennis Frisman and Dr. Elizabeth Hammond, these updates add 125 new...

2012-03-17 23:00:48

Visiopharm´s rapidly expands the APPCenter and showcases over 30 APPs for cancer research, diabetes, neuroscience, respiratory and much more. APPs are created and validated in collaboration between experts in the field and Visiopharm application scientists and programmers. Experts benefit from the collaboration through Visiopharm´s new customer Contributor Program. The Contributor Program offers customers of the APPCenter the ability to earn discounts. A 30% or 50% discount is...